114 related articles for article (PubMed ID: 7433906)
1. 1 alpha-hydroxyvitamin D3 in intestinal calcium malabsorption. A pilot study.
Hylander E; Jarnum S
Scand J Gastroenterol; 1980; 15(4):443-8. PubMed ID: 7433906
[TBL] [Abstract][Full Text] [Related]
2. 1 alpha-hydroxyvitamin D3 treatment of therapy-resistant symptomatic hypocalcemia in a hypoparathyroid patient with intestinal malabsorption.
Hylander E; Madsen S
Acta Med Scand; 1979; 205(7):603-5. PubMed ID: 474189
[TBL] [Abstract][Full Text] [Related]
3. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
Peacock M; Gallagher JC; Nordin BE
Lancet; 1974 Mar; 1(7854):385-89. PubMed ID: 4131034
[No Abstract] [Full Text] [Related]
4. Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Eriksson S
Scand J Rheumatol; 1982; 11(1):55-7. PubMed ID: 7063813
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
7. Osteomalacia and celiac disease: response to 25-hydroxyvitamin D.
Hepner GW; Jowsey J; Arnaud C; Gordon S; Black J; Roginsky M; Moo HF; Young JF
Am J Med; 1978 Dec; 65(6):1015-20. PubMed ID: 742623
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
[TBL] [Abstract][Full Text] [Related]
9. Comparative absorption of vitamin D3 and 25-hydroxyvitamin D3 in intestinal disease.
Davies M; Mawer EB; Krawitt EL
Gut; 1980 Apr; 21(4):287-92. PubMed ID: 6253363
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of combined use of 1 alpha-hydroxyvitamin D3 with calcium supplements in the treatment of osteoporosis].
Yoshikawa S; Ohno A; Moro K; Matsumoto M; Nemoto H; Seki H; Kaneko N; Hosokawa O; Ishijima H
Nihon Seikeigeka Gakkai Zasshi; 1988 Aug; 62(8):723-32. PubMed ID: 3235892
[TBL] [Abstract][Full Text] [Related]
11. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
[TBL] [Abstract][Full Text] [Related]
12. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study.
Braun JJ; Birkenhäger-Frenkel DH; Rietveld AH; Juttmann JR; Visser TJ; Birkenhäger JC
Clin Endocrinol (Oxf); 1983 Aug; 19(2):265-73. PubMed ID: 6349865
[No Abstract] [Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. Impairment of vitamin D metabolism and bone mineral content after intestinal bypass for obesity. A longitudinal study.
Rickers H; Christiansen C; Balslev I; Rødbro P
Scand J Gastroenterol; 1984 Mar; 19(2):184-9. PubMed ID: 6609420
[TBL] [Abstract][Full Text] [Related]
15. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
16. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
[TBL] [Abstract][Full Text] [Related]
18. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
19. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
20. Calcium balance and bone mineral content following small-intestinal resection.
Hylander E; Ladefoged K; Madsen S
Scand J Gastroenterol; 1981; 16(2):167-76. PubMed ID: 6797040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
